Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

GKB OPHTHALMICS LTD.

NSE : NABSE : 533212ISIN CODE : INE265D01015Industry : Medical Equipment/Supplies/AccessoriesHouse : GKB

BSE90.09-2.09 (-2.27 %)

PREV CLOSE ( ) 92.18

OPEN PRICE ( ) 92.18

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 5322

TODAY'S LOW / HIGH ( )89.16 94.80

52 WK LOW / HIGH ( ) 74.1136.4

NSE

This Company is not listed in NSE

Select year

Particulars

Mar 2024

Mar 2023

Mar 2022

Mar 2021

Mar 2020

Operational & Financial Ratios

Earnings Per Share (Rs)

-5.58

-0.33

2.53

-1.80

-3.65

CEPS(Rs)

-0.17

5.84

9.15

4.75

2.32

DPS(Rs)

0.00

Book NAV/Share(Rs)

118.58

124.38

125.17

124.30

117.55

Tax Rate(%)

-7.43

16.57

0.12

19.40

0.00

Margin Ratios

Core EBITDA Margin(%)

0.66

4.88

6.83

3.37

3.65

EBIT Margin(%)

-0.99

2.40

4.83

1.94

-1.69

Pre Tax Margin(%)

-3.15

0.18

2.74

-1.63

-4.19

PAT Margin (%)

-3.38

0.15

2.74

-1.32

-4.19

Cash Profit Margin (%)

-0.09

3.90

6.50

4.21

2.00

Performance Ratios

ROA(%)

-2.55

0.10

1.73

-0.69

-2.41

ROE(%)

-4.87

0.18

3.09

-1.23

-4.41

ROCE(%)

-1.20

2.44

4.58

1.48

-1.38

Asset Turnover(x)

0.75

0.66

0.63

0.53

0.58

Sales/Fixed Asset(x)

1.88

1.63

1.53

1.16

Working Capital/Sales(x)

2.14

1.78

1.93

1.58

1.87

Efficiency Ratios

Fixed Capital/Sales(x)

0.53

0.61

0.65

0.86

Receivable days

116.09

114.24

100.29

142.44

151.07

Inventory Days

162.86

184.84

188.10

211.22

181.31

Payable days

173.79

190.02

200.80

234.20

221.09

Valuation Parameters

PER(x)

0.00

36.39

0.00

PCE(x)

-527.15

18.58

10.05

17.26

18.53

Price/Book(x)

0.74

0.87

0.73

0.66

0.37

Yield(%)

0.00

EV/Net Sales(x)

0.43

0.68

0.59

0.63

0.39

EV/Core EBITDA(x)

18.04

11.17

6.95

8.29

8.74

EV/EBIT(x)

-43.11

28.40

12.18

32.62

-23.31

EV/CE(x)

0.53

0.70

0.37

0.33

0.22

M Cap / Sales

0.50

0.72

0.65

0.73

0.37

Growth Ratio

Net Sales Growth(%)

16.93

6.40

24.72

-2.83

2.40

Core EBITDA Growth(%)

-54.76

-23.22

38.13

65.05

-20.76

EBIT Growth(%)

-148.14

-47.08

210.17

211.85

-362.64

PAT Growth(%)

-2664.14

-94.02

359.73

69.46

-100.59

EPS Growth(%)

-1578.92

-113.14

240.42

50.67

-53.40

Financial Stability Ratios

Total Debt/Equity(x)

0.19

0.18

0.19

0.26

Current Ratio(x)

1.89

2.03

1.95

1.94

1.76

Quick Ratio(x)

1.03

1.09

0.98

1.01

1.02

Interest Cover(x)

-0.46

1.08

2.32

0.54

-0.67

Total Debt/Mcap(x)

0.26

0.20

0.25

0.29

0.70